NASDAQ:ADMA ADMA Biologics (ADMA) Stock Price, News & Analysis $15.69 +0.02 (+0.13%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About ADMA Biologics Stock (NASDAQ:ADMA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ADMA Biologics alerts:Sign Up Key Stats Today's Range$15.37▼$15.7650-Day Range$15.62▼$20.7252-Week Range$3.09▼$21.13Volume2.91 million shsAverage Volume3.63 million shsMarket Capitalization$3.64 billionP/E Ratio112.07Dividend YieldN/APrice Target$15.50Consensus RatingBuy Company OverviewADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Read More… War on Elon Escalates… (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. ADMA Biologics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks43rd Percentile Overall ScoreADMA MarketRank™: ADMA Biologics scored higher than 43% of companies evaluated by MarketBeat, and ranked 511th out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.6 / 5Analyst RatingBuy Consensus RatingADMA Biologics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageADMA Biologics has only been the subject of 2 research reports in the past 90 days.Read more about ADMA Biologics' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth28.57% Earnings GrowthEarnings for ADMA Biologics are expected to grow by 28.57% in the coming year, from $0.49 to $0.63 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADMA Biologics is 112.07, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 130.00.Price to Earnings Ratio vs. SectorThe P/E ratio of ADMA Biologics is 112.07, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 142.79.Price to Book Value per Share RatioADMA Biologics has a P/B Ratio of 26.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ADMA Biologics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.37% of the outstanding shares of ADMA Biologics have been sold short.Short Interest Ratio / Days to CoverADMA Biologics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ADMA Biologics has recently increased by 37.52%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldADMA Biologics does not currently pay a dividend.Dividend GrowthADMA Biologics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.37% of the outstanding shares of ADMA Biologics have been sold short.Short Interest Ratio / Days to CoverADMA Biologics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ADMA Biologics has recently increased by 37.52%, indicating that investor sentiment is decreasing significantly. News and Social Media1.1 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 7 news articles for ADMA Biologics this week, compared to 5 articles on an average week.Search Interest51 people have searched for ADMA on MarketBeat in the last 30 days. This is an increase of 6% compared to the previous 30 days.MarketBeat Follows24 people have added ADMA Biologics to their MarketBeat watchlist in the last 30 days. This is an increase of 243% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ADMA Biologics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,224,121.00 in company stock.Percentage Held by InsidersOnly 3.70% of the stock of ADMA Biologics is held by insiders.Percentage Held by Institutions75.68% of the stock of ADMA Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ADMA Biologics' insider trading history. Receive ADMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address ADMA Stock News HeadlinesADMA STOCK ALERT: Why is ADMA Biologics being Sued for Securities Fraud? Investors that Lost Money are Notified to Contact BFA Law after Stock Drops 20% (Nasdaq:ADMA)October 23 at 6:37 AM | globenewswire.comADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into ADMA Biologics Inc and Encourages Investors to Contact the FirmOctober 21 at 4:00 PM | globenewswire.comUrgent: This election is riggedIf you missed it, my emergency election broadcast is now available - but will be removed soonOctober 24, 2024 | Porter & Company (Ad)ADMA INVESTIGATION NEWS: The Securities Fraud Investigation into ADMA Biologics, Inc. after Stock Drops 20% is Ongoing; Contact BFA Law if You Lost Money (Nasdaq:ADMA)October 21 at 6:08 AM | globenewswire.comADMA INVESTIGATION UPDATE: ADMA Biologics Investors are Notified of Securities Fraud Investigation into Auditor Resignation; Contact BFA Law if You Lost Money (Nasdaq:ADMA)October 19, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMAOctober 17, 2024 | prnewswire.comADMA Biologics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover LossesOctober 17, 2024 | globenewswire.comADMA FRAUD NOTICE: Lost Money on Your ADMA Biologics, Inc. Securities? Contact BFA Law about its Investigation into the Company after Auditor Resigns (Nasdaq:ADMA)October 17, 2024 | globenewswire.comSee More Headlines ADMA Stock Analysis - Frequently Asked Questions How have ADMA shares performed this year? ADMA Biologics' stock was trading at $4.52 at the beginning of the year. Since then, ADMA stock has increased by 247.1% and is now trading at $15.69. View the best growth stocks for 2024 here. How were ADMA Biologics' earnings last quarter? ADMA Biologics, Inc. (NASDAQ:ADMA) posted its earnings results on Thursday, August, 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.05. The business's quarterly revenue was up 78.4% on a year-over-year basis. Who are ADMA Biologics' major shareholders? ADMA Biologics' top institutional shareholders include Assenagon Asset Management S.A. (1.50%), Raymond James & Associates (0.11%), Allspring Global Investments Holdings LLC (0.10%) and Louisiana State Employees Retirement System (0.05%). Insiders that own company stock include Steve Elms, Adam S Grossman, Brian Lenz, Jerrold B Grossman, Kaitlin M Kestenberg-Messina, Young Kwon, Lawrence P Guiheen and Bryant Fong. View institutional ownership trends. How do I buy shares of ADMA Biologics? Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ADMA Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that ADMA Biologics investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings8/08/2024Today10/23/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADMA CUSIPN/A CIK1368514 Webwww.admabiologics.com Phone(201) 478-5552Fax201-478-5553Employees530Year FoundedN/APrice Target and Rating Average Stock Price Target$15.50 High Stock Price Target$20.00 Low Stock Price Target$10.00 Potential Upside/Downside-1.2%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.02) Trailing P/E Ratio112.07 Forward P/E Ratio32.02 P/E GrowthN/ANet Income$-28,240,000.00 Net Margins10.53% Pretax Margin11.86% Return on Equity38.79% Return on Assets17.35% Debt Debt-to-Equity Ratio0.74 Current Ratio6.87 Quick Ratio2.80 Sales & Book Value Annual Sales$330.24 million Price / Sales11.01 Cash Flow$0.04 per share Price / Cash Flow399.96 Book Value$0.60 per share Price / Book26.15Miscellaneous Outstanding Shares231,809,000Free Float224,459,000Market Cap$3.64 billion OptionableOptionable Beta0.62 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for November 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:ADMA) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADMA Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ADMA Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.